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A B S T R A C T
Purpose: We sought explore the eﬀects of doxorubicin on sleep patterns and locomotor activity. To investigate
these eﬀects, two groups were formed: a control group and a Doxorubicin (DOXO) group.
Methods: Sixteen rats were randomly assigned to either the control or DOXO groups. The sleep patterns were
examined by polysomnographic recording and locomotor activity was evaluated in an open-ﬁeld test.
Results: In the light period, the total sleep time and slow wave sleep were decreased, while the wake after sleep
onset and arousal were increased in the DOXO group compared with the control group (p < 0.05). In the dark
period, the total sleep time, arousal, and slow wave sleep were increased, while the wake after sleep onset was
decreased in the DOXO group compared with the control group (p < 0.05). Moreover, DOXO induced a decrease
of crossing and rearing numbers when compared control group (p < 0.05).
Conclusions: Therefore, our results suggest that doxorubicin induces sleep pattern impairments and reduction
of locomotor activity.
1. Introduction
Although sleep is essential for good health and quality of life,
according to Bonnet and Arand [1], one-third or more of normal adults
suﬀer from signiﬁcant sleep loss. In addition, several studies have
shown that cancer chemotherapy treatment with doxorubicin alters
sleep patterns and health status, leading to distressing symptoms and
fatigue [2–4].
Doxorubicin (DOXO), a member of the antineoplastic antibiotic
family of anthracyclines, is a chemotherapeutic agent developed in the
1960s [5], that is still widely used in the treatment of a variety of
malignancies, such as acute leukemia, non-Hodgkin lymphomas, breast
cancer, Hodgkin's disease, and sarcomas [6,7].
Savard et al. [4] showed that breast cancer patients treated with
doxorubicin have impaired sleep-wake activity rhythms. Moreover, the
ﬁrst administration of chemotherapy is associated with a disruption of
the sleep-wake rhythm, and the repeated administration of this
chemotherapy results in more enduring impairments of the sleep-wake
rhythms. Moreover, the DOXO treatment in breast cancer women is
associated with disturbance sleep, sleep eﬃciency and poor sleep
quality [8].
Neural systems implicated in the control of sleep also impact the
functioning of host defenses. The challenge for future research is to
determine the ultimate implication of the sleep loss eﬀects in molecular
terms to clarify the mechanistic processes involved in the impairment
of cellular functional activity, and the impact of sleep deprivation on
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other essential inﬂammatory markers for immune function [9]. On the
other hand, other studies have reported that chemotherapy may
promote and/or aggravate inﬂammation status which impairs sleep
quality [10,11].
Therefore, in this study, we sought to determine eﬀects of DOXO on
the sleep pattern and locomotor activity in the rats.
2. Methods
2.1. Animals
The Experimental Research Committee of the Universidade Federal
de São Paulo approved all procedures for the care of the animals used
in this study (0619/09). A total of 16 male Wistar rats approximately
14 weeks of age (weighing 350–380 g) were used. They were housed
four per cage in an animal room under a 12-h light-dark cycle at 22 ±
1 °C and 60 ± 5% humidity and received a chow diet and water ad
libitum. The experiments were carried out after a one-week acclimation
period. The rats were randomly divided into two groups: (i) a saline
Control group (n=8) and (ii) a doxorubicin (DOXO) group (n=8).
2.2. Design
In the ﬁrst day the animal were subjected to electrode insertion
surgery. Seven days after surgery (ninth day), the animal received
doxorubicin cloridrato (Eurofarma Laboratory, Campinas, Brazil)
(15 mg/kg, i.p.) [12] or saline (i.p.). The sleep recording was conducted
for 24 h (12-h light-dark) after 48 h doxorubicin-treatment (a single
administration) and the locomotor activity was evaluated 48 h after
doxorubicin-treatment in the open-ﬁeld test. The doxorubicin and
saline were administered at 7:00 AM.
2.3. Experimental Protocols
2.3.1. Surgical preparation
The rats were anesthetized with diazepam and ketamine (5 and
100 mg/kg body weight, i.p., respectively). They were then placed in
the stereotaxic apparatus, and two bipolar electrodes with 4 stainless-
steel screws (Ø 0.9 mm) were placed into the skull through small holes
bored into the right lateral frontoparietal region (1 pair of screws) and
the left medial frontoparietal region (another pair) in order to monitor
the bipolar electrocorticogram (ECoG) [13].
For the electromyography recording (EMG), one pair of electrodes
was inserted in the cervical musculature. After the electrode insertion
surgery, the rats were placed in individual compartments for 7 days of
recovery and then given 2 days of adaptation while connected to the
polysomnographic recording (PSG) device.
2.3.2. Electrocorticography recording
During the Electrocorticography (ECoG) recording, the rats re-
mained in individual compartments with unrestricted access to food
and water. The ECoG recording was made with a Nihon-Kohden model
QP 223 polygraph (digital signal acquisition) using three pairs of
channels: two ECoG and one EMG for the cervical musculature. The
recording was analyzed for two 12 h periods (12-h light–dark). In the
literature, rats were shown to have 62% sleep eﬃciency during the light
period (7:00–19:00 h) and 33% during the dark period (19:00–7:00 h)
[14]. Each 10 s period was classiﬁed in accordance with Timo-Iaria
et al. [15]: wakefulness (W) was deﬁned as low amplitude waves with
fast ECoG and EMG activation; slow wave sleep (SWS) was deﬁned as
high amplitude waves and slow ECoG and EMG activation; and
paradoxical sleep was deﬁned (PS) as fast ECoG activity, the regular
presence of a theta hippocampal rhythm and the absence of EMG
activity. At the end of the analysis, the sleep parameters were
quantiﬁed using the Polysmith Software program®.
The sleep parameters collected were the following: sleep eﬃciency
(SE; percentage of total sleep time during the recording period),
latency to sleep (time lag between the start of the recording and the
ﬁrst sleep period), slow wave sleep (SWS; percentage of all periods
featuring high delta content during the recording period), paradoxical
sleep (PS; percentage of all periods during the recording period), PS
latency (time lag between the start of the recording and the ﬁrst PS
period), wake after sleep onset (WASO; percentage of all periods of
wakefulness throughout the recording period number of awakenings)
and number of arousals (number of awakenings).
2.3.3. Open-ﬁeld test
The rats were treated with doxorubicin (15 mg/kg), and saline 48 h
before the exposure to the open-ﬁeld apparatus (light phase), in order
to assess the possible eﬀects of drug treatment on spontaneous
locomotor activity. Analysis of the rat's spontaneous activity was
carried out in an open ﬁeld apparatus, which is a 45 cm×60 cm arena
surrounded by 50 cm high walls made of brown plywood with a frontal
glass wall. The ﬂoor of the open ﬁeld was divided into 9 rectangles
(15 cm×20 cm each) by black lines [16]. Animals were gently placed on
the left rear quadrant, and left to explore the arena for 5 min. The
number of horizontal (crossings) and vertical (rearings) activities
performed by each rat during the 5 min observation period was
counted by an expert observer.
2.4. Statistical analysis
The statistical analysis was performed using the GraphPad Prism
statistics software package version 5.0 for Windows (GraphPad
Software, San Diego, CA, USA). The data are expressed as the mean
± SEM. Implementation of the Kolmogorov-Smirnov test revealed that
the results of the experiments were distributed normally. The data were
analyzed using two-way ANOVA followed by the Tukey test and
unpaired Student's t-test for comparison between the two groups. A
value of P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Doxorubicin administration impairs the sleep pattern
A signiﬁcant increase was detected on the wakefulness of the DOXO
group in light period in relation to control group. Statistical diﬀerences
were found in both the light/dark period in the DOXO and control
groups for wakefulness. In addition, the Sleep Eﬃciency of the DOXO
group demonstrated a signiﬁcant decrease in relation to the control
group in the light period group; no statistical diﬀerences were found in
either the light/dark period in the DOXO group to Sleep Eﬃciency.
Fig. 1.
The sleep parameter data are shown in Table 1. The two-way
ANOVA revealed the main eﬀects of the group (arousal), time (TST,
Fig. 1. Wakefulness (%) and Sleep Eﬃciency (%) during light and dark periods of sleep
in both Control (CTRL) and Doxorubicin (DOXO) groups. Two-way ANOVA followed by
the Tukey post hoc test (p < 0.05) comparison of groups for the time factor (# diﬀer Light
Control; & diﬀer Light DOXO). The bars mark of periods light (left) and dark (right) of
sleep. Animals: CTRL (n=8), DOXO (n=8). Dose: 15 mg/kg, (i.p.) – DOXO or saline.
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WASO and arousal) as well as an interactive eﬀect between these
factors (TST, WASO and SWS). During the light period, the total sleep
time (min) and slow wave sleep (%) were decreased, while the wake
after sleep onset (min) and arousal were increased in the DOXO group
compared with the control group (light period) (p < 0.05). In contrast,
during the dark period, the total sleep time (min), arousal and slow
wave sleep (%) were increased, while the wake after sleep onset (min)
was decreased in the DOXO group compared with the control group
(dark period) (p < 0.05).
3.2. Doxorubicin leads to decreased locomotor activity when
evaluated by open ﬁeld test
The results depicted in Fig. 2A show the eﬀect of rats treated with
Doxorubicin or vehicle on the locomotor activity in the open ﬁeld test.
T-test revealed signiﬁcant diﬀerences for control and DOXO groups
(t(19): 7.72; p < 0.01), indicating that doxorubicin induced a reduction
of locomotor activity. The Fig. 2B indicated that doxorubicin induced
low exploratory activity. T-test revealed signiﬁcant diﬀerences for
control and DOXO group (t (19): 6.61; p < 0.01). The Open Field
Test was performed for 48 h and 72 h (data not shown) after DOXO.
However, the results were the same, thus we chose the results from the
48 h (OFT) test to assess the animals’ locomotor activity before
evaluating their sleep patterns.
4. Discussion
The purpose of the present study was to examine the eﬀect of a
single administration of DOXO (15 mg/kg) on sleep-wake cycles and
locomotor activity. This study demonstrated that a single administra-
tion of DOXO had impaired the sleep pattern and reduced the
locomotor activity of rats.
These changes are relevant because these alterations negatively
impact the quality of life of chemotherapy patients, leading to higher
levels of fatigue [17]. Borniger et al. [18] demonstrated in adult female
c57bl/6 mice that 13.5 mg/kg doxorubicin and 135 mg/kg cyclopho-
sphamide increased Non Rapid Eye Movement (NREM) and Rapid Eye
Movement (REM) sleep during subsequent active (dark) phases; this
induced sleep was fragmented and of low quality. Similarly, our results
demonstrated an increased in NREM/SWS (dark phase) and fragmen-
ted alterations with DOXO treatment, being that the fragmentation can
be seen in increased arousal index of DOXO group; i.e. how often the
animal came into wakefulness per hour (DOXO group – Light phase:
21.98 arousal/hour; Dark phase: 23.39 arousal/hour versus Control
group – Light phase: 10.63 arousal/hour; Dark phase: 12.57 arousal/
hour).
In the present study, the rats presented disrupted circadian
rhythms after DOXO treatment. Sleep eﬃciency showed no statistical
diﬀerences in either the light or dark periods, thus, the light and dark
period presented similar sleep eﬃciency levels. This is contrary to the
pattern reported by Van Luijtelarr and Coenen [14] which presented
62% predominance of sleep in the light period and 33% in the active or
dark period.
Last year, it was recognized that DOXO reaches the brain capillary
endothelial cells by a P-glycoprotein, leading to attenuated blood-brain
barrier (BBB) permeation. Likewise, P-glycoprotein inhibitors at the
BBB may increase drug concentrations in the central nervous system
[19,20]. Likewise, several studies have reported that chemotherapeu-
tics, such as DOXO, activate the immune system with an increased
inﬂammatory cytokine release in both central and peripheral tissues
which induces sleep problems [10,11]. This peripheral-CNS axis occurs
by transport of cytokines to the brain via the vagus nerve [21]. This
likely explains the role of pro-inﬂammatory cytokines in vigilance state.
Hogan and collaborators injected IL6 indirectly into the CNS from
rodents and found enhanced sleep fragmentation [22]. Moreover, it
was observed in women diagnosed with stage I–III breast cancer
Table 1
Sleep pattern in Control and Doxorubicin groups during the light and dark periods (12-h light–dark).
Sleep pattern Control DOXO ANOVA F
Light Dark Light Dark Time Group Interaction
Total Sleep Time (min) 443.35 ± 78.85* 212.75 ± 28.96 332.44 ± 63.39*# 268.98 ± 44.37*# 29.811a 1.030 9.63c
Wake after Sleep Onset (min) 256.22 ± 88.31 500.17 ± 24.76 362.72 ± 57.26*# 442.80 ± 33.65*# 38.083a 0.875 9.740c
Latency Sleep (min) 17.97 ± 32.10 6.80 ± 11.36 20.58 ± 15.25 6.18 ± 9.50 2.132 0.012 0.033
Arousal 78.50 ± 12.66 44.50 ± 14.79 121.80 ± 26.19*# 104.80 ± 33.70* 4.802a 19.815b 0.533
PS Latency (min) 64.75 ± 82,03 24.45 ± 22.34 47.28 ± 31.80 55.50 ± 82.16 0.303 0.054 0.694
Slow Wave Sleep (%) 54.42 ± 9.28* 26.80 ± 3.54 40.56 ± 9.01*# 34.96 ± 6.10*# 22.288 0.657 9.794c
Paradoxal sleep (%) 9.15 ± 2.71* 2.97 ± 0.37 7.22 ± 1.45* 2.74 ± 1.21*# 47.836 1.975 1.210
P≤0.05 comparing groups for the atime factor, bgroup factor and cinteraction (two-way ANOVA followed by the Tukey test). # diﬀer Light Control; * diﬀer Dark Control; & diﬀer Light
DOXO. Animals: CTRL (n=8), DOXO (n=8). Dose: 15 mg/kg, (i.p.) – DOXO or saline.
Fig. 2. Eﬀect of treatment with doxorubicin on locomotor activity evaluated in the open-ﬁeld test. The results are shown as the number of crossings (panel 1A) and the number of
rearing (panel 1B). The results are expressed as the mean ±MSD (n=9–12). **p < 0.01 when compared to control group. Animals: CTRL (n=8), DOXO (n=8). Dose: 15 mg/kg, (i.p.) –
DOXO or saline.
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receiving chemotherapy, that blood IL6, C-reactive protein and IL1ra
concentrations are associated with sleep fragmentation [23]. Recently,
a correlation between IL6 mRNA expression and disruption sleep in
health rats was identiﬁed [18].
Another important consideration in our study is the apparent
decrease in locomotor activity and exploratory behavior observed in
the rats after 48 h of DOXO intraperitoneal treatment. The results of
the present work demonstrated that DOXO reduced the crossing and
rearing number in the open ﬁeld test. A study performed by Liedke
et al. [24] showed that animals treated with DOXO (0.5, 2 and 8 mg/
kg), evaluated in the open ﬁeld 20 min after DOXO, presented no
diﬀerences in anxiety, locomotor activity and exploratory behavior. On
the other hand, when the animals were tested 24 h after DOXO
treatment a reduced rearing number was observed, suggesting that
DOXO can interfere with exploratory behavior. Several studies have
previously shown that sleep alterations and sleep-deprived rats exhibit
body weight loss and elevated corticosterone levels [25–27]. The
immediate purpose of glucocorticoid release during stress situations
is to provide readily usable energy (i.e., glucose to the central nervous
system). This release is accomplished together with catecholamines,
GH and glucagon, to induce lipolysis, glycogenolysis, gluconeogenesis
and, in cases of severe and prolonged stress, proteolysis [28]. These
alterations can play an important role in the onset and maintenance of
wasting found in the DOXO treatment. A study performed by Kaur
et al. [29] showed that rats subjected to restraint stress demonstrated a
reduction of locomotor and exploratory activity. Liu et al. [30] showed
similar results in the chronic, unpredicted mild stress in rats.
Moreover, stress is involved with the increase of corticosterone level
as well reduction of locomotor activity and exploratory behavior in rats
[31]. These results indicated that DOXO appears to induce a stress-like
state. Recently, de Lima Junior [32] has showed that DOXO leads to
conditions similar to cachexia, with severe glucose intolerance both in
vivo and in vitro. We suggest that DOXO promotes less muscle mass,
strength, and function, supporting the decrease in locomotor activity.
However, this hypothesis is speculative and, therefore, further studies
are needed.
A point to note in the study was the dose of Doxo used in the
procedure. This is not really used in clinical practice, however, this dose
is currently used in several studies for analyzed of acute toxicity in the
characterization of the molecular pathways in cardiotoxicity, sarcope-
nia and autophagy in skeletal muscle [33–35].
In this context, our results suggest that doxorubicin induces sleep
pattern impairment that is accompanied by locomotor activity altera-
tions. Thus, although it is eﬀective in promoting tumor cell death, this
chemotherapy causes severe damage to the sleep and locomotor
behavior decreasing patient quality of life.
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